Therapy efficacy in patients with Non-Hodgkin’s Lymphomas with rituximab
Summary. The group of 210 patients with B-cell Non-Hodgkin’s Lymphoma was chosen for the study of the efficacy of treatment with rituximab. Retrospective analysis was performed for the evaluation of immediate and distant results of the treatment. The increase of the overall response in study group on 23% in comparence to the control group was detected. 5-year survival in the study group was 69,4±6,4% and 49,1±7,3% in control group (р<0,05). The results of the treatment were better in the group treated with rituximab.
No Comments » Add your